COMMUNIQUÉS West-GlobeNewswire

Sport Endurance Engages INFOR Financial as Financial Advisor
14/12/2018
BROOKLYN, N.Y., Dec. 14, 2018 (GLOBE NEWSWIRE) -- Sport Endurance, Inc. (OTCQB: SENZ) (the “Company”), announced today that it has retained INFOR Financial Inc. (“INFOR Financial”) to provide financial advisory services [...]
WishBone Medical, Inc. signs licensing agreement for the Guided Growth Plate
14/12/2018
WARSAW, Ind., Dec. 14, 2018 (GLOBE NEWSWIRE) -- WishBone Medical, Inc. has been granted a global, non-exclusive license for the sale of a patented guided growth plating system in children with deformed limbs. These 3 [...]
Orchard Therapeutics and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing Efficiency
14/12/2018
BOSTON and LONDON and MARTINSRIED, Germany, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients [...]
Radient Technologies Inc. Ready to Serve $22B U.S. Market for Hemp-Derived CBD
14/12/2018
EDMONTON, Alberta, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI ) is encouraged by the approval by the U.S. Senate and House of Representatives of the 2018 [...]
Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO
14/12/2018
Rimiducid-activated GoCAR-T ® resulted in significant expansion and persistence of T cells Initial evidence of biologic activity and stable disease observed in some patients with single rimiducid dose BPX-601 was well- [...]
Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
14/12/2018
- 32.4% of patients evaluable for efficacy achieved partial response or better; 76.5% of patients achieved disease control - - Tumor shrinkage observed in both injected and uninjected lesions, indicating an abscopal [...]
iKang Enters into Amendment No. 3 to Merger Agreement for Going Private Transaction
14/12/2018
BEIJING, Dec. 14, 2018 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced [...]
The Finnish Competition and Consumer Authority has given the final approval for the transaction between Terveystalo and Attendo which is intended to be completed on 28 December 2018
14/12/2018
Terveystalo Plc Stock exchange release 14 December 2018 at 13:00 EET Terveystalo signed an agreement on 17 May 2018 to acquire the Finnish healthcare operations of Attendo AB. The Finnish Competition and Consumer [...]
The Ensign Group, Inc. Increases Quarterly Dividend to $0.0475 Per Share
14/12/2018
MISSION VIEJO, Calif., Dec. 14, 2018 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ: ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health, home care, hospice [...]
Santhera Raises Gross Proceeds of CHF 23.5 Million and Secures Acquisition of Option to Vamorolone Sub-license
14/12/2018
Pratteln, Switzerland, December 14, 2018 - Santhera Pharmaceuticals Holding AG (SIX: SANN) has completed its ordinary capital increase with the placement of 3,133,334 new shares by way of an accelerated bookbuilding and [...]
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
14/12/2018
Company announcement – No. 31 / 2018 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, December 14, 2018 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), a [...]
Santhera Provides Update on the Share Placement
14/12/2018
Pratteln, Switzerland, December 14, 2018 - Santhera Pharmaceuticals Holding AG (SIX: SANN) provides an update on the accelerated bookbuilding. On December 12, 2018, Santhera Pharmaceuticals Holding AG announced the [...]
FIT Biotech Oy: FIT Biotech's financial calendar and Annual General Meeting in 2019
14/12/2018
FIT Biotech Oy Company release 14.12.2018 at 09:00 AM EET FIT Biotech's financial calendar and Annual General Meeting in 2019 During the year 2019, FIT Biotech Oy will publish the Financial Statement release 2018 and [...]
Rule 2.9 Announcement
14/12/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 14 December 2018 [...]
Sensorion Announces Positive Topline Results From Seliforant Phase 2a Study
14/12/2018
Results confirmed Seliforant does not affect vigilance, cognitive performance during a motion stimulus MONTPELLIER, France, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN) , a pioneering clinical- [...]
Dentsply Sirona Declares Quarterly Cash Dividend
14/12/2018
YORK, Pa., Dec. 13, 2018 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (NASDAQ: XRAY), The Dental Solutions Company TM , announced that its Board of Directors declared a quarterly cash dividend of $0.0875 [...]
Canada House Wellness Group Reports Second Quarter Fiscal Year 2019 Results
14/12/2018
54% Increase in Revenue compared to the same Period in the Prior Year NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Canada House Wellness [...]
Genmab Announces Submission of Supplemental New Drug Application for Daratumumab in Front Line Multiple Myeloma in Japan
14/12/2018
Company Announcement Supplemental new drug application submitted in Japan for daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma [...]
Extendicare Announces December 2018 Dividend of C$0.04 per Share
14/12/2018
MARKHAM, Ontario, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]

Pages